However, the antitumor effect exerted by the combination of ATR inhibitor with topoisomerase (TOP1) inhibitor and the subsequent mechanisms underlying enhanced tumor immunogenicity in SCLC remain poorly understood. This evidence concerns the gene ATR and small cell lung carcinoma.